A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

World’s First Fully Transparent Surgical Mask Receives FDA (510k) Clearance

The world’s first fully transparent surgical mask has received FDA clearance. The news was announced today by ClearMask LLC.

ClearMask™ is the world’s first FDA-cleared, fully transparent surgical mask that can be used in hospitals, clinics, schools, retail, hospitality, and other settings. The mask is optimized for maximum clarity and comfort, and meets applicable ASTM Level 3 requirements for fluid resistance and flammability, which offers a high level of protection for medical use in environments such as operating rooms.

In this disheartening time as the world fights against the COVID-19 pandemic, the ClearMask™ helps provide protection while bringing much-needed relief through a reassuring smile and familiar face among fear, confusion, and suffering. In addition to blocking particles or droplets with its fully transparent, anti-fog plastic barrier, the ClearMask™ helps improve visual communication, which may help avoid costly errors and adverse outcomes. Transparent communication during the customer experience can be critical in establishing rapport and earning trust, while assuring safety as a priority.

The company, consisting of Johns Hopkins University graduate students and alumni, started developing the transparent mask in 2017 after their deaf co-founder experienced an adverse experience during her surgery. Traditional surgical masks blocked her providers’ faces, impeding effective communication and safety.

“After three years of research, development, and testing, we are thrilled to bring a human-centered mask to everyone who needs it, especially those who can benefit from improved visual communication, such as children, older adults, deaf and hard of hearing people, and those who do not speak the same language. The ClearMask™ is well-positioned to join the fight against the current pandemic,” said Allysa Dittmar, President of ClearMask.

The ClearMask™ is the first product in ClearMask LLC’s growing portfolio of novel masks to receive FDA clearance as a Class II medical device. To fulfill the current and rising demand as the company ramps up production of the FDA-cleared mask, the company is currently offering a non-medical, consumer face mask that similarly helps to improve visual communication and provide protection at a lower price. The consumer masks have provided much relief to different communities in need, including state emergency management agencies and essential workers.

To date, the company has provided the masks in bulk volumes, typically in the tens to hundreds of thousands. The consumer masks can now be purchased through ClearMask’s website at buy.theclearmask.com, starting at a box of 24 masks. The company has partnered with several distributors, including Cardinal Health Canada, McKesson, Oaktree Products, and Grainger to help get the masks out to as many people as possible.

“Regulatory clearance and mass production are two significant milestones in ClearMask’s mission to get the ClearMask out to as many people as possible,” said Aaron Hsu, CEO of ClearMask. “This achievement is a testament to our company’s hard work and commitment to serving different communities in need during this time.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy